Solventum Corporation $SOLV Shares Bought by Barrett & Company Inc.

Barrett & Company Inc. grew its holdings in shares of Solventum Corporation (NYSE:SOLV) by 206.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 398 shares of the company’s stock after purchasing an additional 268 shares during the period. Barrett & Company Inc.’s holdings in Solventum were worth $30,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rossby Financial LCC acquired a new position in Solventum during the 1st quarter worth approximately $25,000. Strengthening Families & Communities LLC grew its holdings in shares of Solventum by 376.8% in the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock worth $25,000 after acquiring an additional 260 shares during the period. Hara Capital LLC acquired a new stake in shares of Solventum in the 1st quarter worth approximately $38,000. Smartleaf Asset Management LLC grew its holdings in shares of Solventum by 193.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock worth $40,000 after acquiring an additional 352 shares during the period. Finally, Costello Asset Management INC acquired a new stake in shares of Solventum in the 1st quarter worth approximately $42,000.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 price target on the stock in a report on Tuesday, July 1st. Zacks Research upgraded Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. UBS Group assumed coverage on Solventum in a report on Wednesday. They issued a “neutral” rating and a $77.00 price target on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Solventum in a report on Saturday, September 27th. Finally, KeyCorp initiated coverage on Solventum in a report on Friday, June 6th. They issued a “sector weight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $84.60.

Solventum Price Performance

SOLV stock opened at $74.03 on Friday. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The stock’s 50 day moving average price is $72.80 and its 200 day moving average price is $72.21. The firm has a market cap of $12.84 billion, a P/E ratio of 34.27, a PEG ratio of 3.03 and a beta of 0.50.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The company had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same quarter in the prior year, the company posted $1.56 EPS. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, sell-side analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.